Does Anthem Cover Weight Loss Injections? Plan-Specific Coverage Checks

Key Takeaways

• The exact Anthem plan's drug list and benefit terms determine coverage. The medication, requested indication, formulary listing and any prior authorization or step-therapy notes must be compared together; an employer-rider rule is not a universal description of all Anthem coverage.
• Anthem does not publish prior authorization approval rates. Correction, September 2026: an earlier version cited a 34% first-submission approval figure attributed to internal PBM data; it could not be verified and has been removed
• Medicare changed on July 1, 2026: the Medicare GLP-1 Bridge, which runs from July 1, 2026 through December 31, 2027 and offers eligible beneficiaries access to Wegovy, the Zepbound KwikPen and Foundayo at $50 a month with prior authorization, outside the $2,100 Part D out-of-pocket cap. Outside the Bridge, Part D still excludes drugs used for weight loss by statute
• Compounded semaglutide had a month-one median of $197 (range $88 to $299 across 14 providers) in the Compounded GLP-1 Price Index as of September 3, 2026, with no prior authorization, but FDA declared the semaglutide shortage resolved on February 21, 2025, so it is no longer available under shortage-based enforcement discretion and depends on a prescriber documenting a patient-specific need

The short answer

Anthem coverage depends on the member's actual plan, medication, indication and benefit terms. A listing for Ozempic or Mounjaro is not an answer about weight-management coverage for Wegovy or Zepbound. Employer-sponsored, individual and public-program coverage need their own current documents. Prior authorization requirements and covered benefits are separate questions. The Medicare and Medi-Cal sections below discuss their specific programs rather than a single rule for every Anthem member.

Four documents answer four different coverage questions

Anthem's pharmacy-information page explains that the drug list's notes identify prior authorization and step therapy, while benefit limitations and exclusions also matter. Reading only one of these fields can produce a confident but incomplete answer.

Question	Document or field	What the result establishes
Which coverage applies to this member?	The exact plan and pharmacy-benefit information	The document set to use; the Anthem brand name alone does not select one national benefit.
Is the exact drug and indication included?	Current drug list and benefit exclusions	Whether the requested use is within the plan's benefit scope.
What must an authorization request contain?	The applicable PA or step-therapy criteria and drug-list notes	The evidence or sequence requested by that plan, separate from benefit inclusion.
What happened to this request?	The actual decision and its stated reason	The specific issue to address, such as a benefit exclusion or missing documentation.

For a concrete counterexample to an employer-only rule, Anthem publishes a Virginia Medicaid weight-loss-management authorization form. Its existence identifies a program-specific authorization process; it does not prove an individual request will be approved. California's published Medi-Cal notice describes a different January 2026 change and specified non-weight-loss indications. These are different programs, not two versions of a universal Anthem policy.

The useful comparison is therefore the same member, exact product, requested indication and effective plan date across the relevant documents. An FDA indication, a formulary entry and an authorization decision each answer a different part of the question.

Primary sources: Anthem pharmacy information; Virginia Medicaid weight-loss-management PA form; California Medi-Cal GLP-1 notice. This comparison was checked October 3, 2026.

Table of contents

1. How Anthem's GLP-1 coverage actually works in 2026
2. The diabetes vs. weight loss coverage split
3. Exact BMI and comorbidity thresholds by plan type
4. The prior authorization process, step by step
5. Why weight-loss-only prior auths so often fail on first submission
6. What most articles get wrong about "medical necessity"
7. The Medicare Advantage exception that catches everyone
8. State-by-state variation in Anthem coverage rules
9. When to appeal and when to switch strategies
10. Compounded semaglutide as the predictable alternative
11. The decision tree: should you fight the denial or move on?
12. Correction (September 2026)
13. Medicare GLP-1 Bridge (July 2026)
14. Medi-Cal change (January 2026)
15. Compounded GLP-1 cost and legal status (September 2026)
16. FAQ

How Anthem's GLP-1 coverage actually works in 2026

Anthem Blue Cross and Blue Shield and its affiliated Blue plans are offered in 14 states (Elevance Health). Pharmacy claims for most Anthem commercial plans run through CarelonRx, Elevance Health's in-house pharmacy benefit manager, which was named IngenioRx until January 1, 2023. Correction, September 2026: earlier versions of this page used the old IngenioRx name and said each state entity had its own PBM contract; both have been corrected.

The coverage architecture has three tiers:

Tier 1: Diabetes indication. Semaglutide (Ozempic), tirzepatide (Mounjaro), dulaglutide (Trulicity), and liraglutide (Victoza) are commonly covered for type 2 diabetes with prior authorization; formularies and the lab documentation required vary by plan, so check your plan's formulary. Cost sharing depends on the plan's tier structure and deductible and is not published in a single Anthem figure.

Tier 2: Commercial weight-management benefits. Coverage for Wegovy or Zepbound depends on the particular plan benefit and medication criteria. An employer-selected benefit is one plan-design situation, not a universal rule for all Anthem members. How many employers do so is not published by Anthem. Correction, September 2026: adoption percentages attributed to an Anthem 2025 benefit design survey (41%, 28%, 52%) could not be verified and have been removed. Self-insured groups control their own benefit design and can add or drop the benefit at renewal.

Tier 3: Limited or no coverage. Medicare Part D, including Anthem Medicare Advantage plans with drug coverage, excludes agents used for weight loss by statute (Social Security Act section 1860D-2(e)(2)(A), incorporating section 1927(d)(2)(A)), alongside a separate demonstration for eligible beneficiaries: the Medicare GLP-1 Bridge, which runs from July 1, 2026 through December 31, 2027 and offers eligible beneficiaries access to Wegovy, the Zepbound KwikPen and Foundayo at $50 a month with prior authorization, outside the $2,100 Part D out-of-pocket cap. Medicaid varies by state: KFF counted 13 states covering GLP-1s for obesity as of January 16, 2026, while California (Medi-Cal), New Hampshire, Pennsylvania and South Carolina ended coverage on January 1, 2026 and MassHealth on July 1, 2026. Grandfathered plans (those in place on March 23, 2010) are exempt from some Affordable Care Act requirements but set their own drug benefits.

The single most common error patients make is assuming that because Anthem "covers Ozempic," it will also cover the same medication prescribed at a higher dose for weight loss. The FDA indication on the prescription determines the coverage pathway, not the molecule.

The diabetes vs. weight loss coverage split

Anthem's pharmacy criteria draw a line between diabetes management and weight loss. The criteria document itself is not publicly retrievable, so what follows is the general pattern, which tracks the FDA labels; confirm specifics with your plan. Correction, September 2026: an earlier version cited a policy number (PHARMACY.00082) that could not be located and has been removed.

Diabetes criteria discussed below, subject to the particular plan:

• Documented type 2 diabetes diagnosis (ICD-10 E11.x)
• Recent laboratory documentation of diabetes, as specified by the plan
• Prescription written by an MD, DO, NP, or PA with diabetes management scope
• No history of medullary thyroid carcinoma or MEN2 syndrome

Weight-management criteria discussed below, subject to the particular plan:

• BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documented lifestyle intervention (diet and physical activity); the required duration varies by plan and is not published in a document this page could retrieve
• Prescription written for an FDA-approved weight-management product (Wegovy or Zepbound at any labeled dose, not Ozempic or Mounjaro)
• No contraindications per the prescribing information

Lifestyle documentation is a common prior authorization failure point. Plans typically accept either:

• A structured weight-loss program enrollment record (e.g., Weight Watchers, Noom, a hospital-based program) with attendance logs, or
• Clinical notes from provider visits over the plan's required period documenting weight, dietary counseling provided, and exercise recommendations given

A single note saying "patient reports trying diet and exercise without success" does not meet the standard. The documentation must show prospective counseling, not retrospective patient report.

Published program examples and their scope

The July 2026 Virginia form supplies a concrete counterexample to using FDA indication thresholds as every plan's authorization criteria. The comparison below keeps that program separate from commercial benefits and California Medi-Cal.

Source scope	What the source establishes	How to interpret it
Anthem pharmacy-information overview	Drug-list notes identify PA and step therapy; plan benefits also have limitations and exclusions.	It provides a way to locate the relevant criteria, not one universal BMI threshold for commercial members.
Virginia Anthem HealthKeepers Plus Medicaid, July 2026 form, page 4	For listed weight-loss GLP-1 products: BMI greater than 40 without applicable risk factors, or greater than 37 with listed risk factors (dyslipidemia, hypertension or type 2 diabetes), alongside other drug-trial and product criteria.	These are that form's criteria. They differ from a generic 30/27 indication threshold and do not describe every Anthem plan.
California Medi-Cal notice, effective January 2026	Weight-loss coverage changed for Wegovy, Zepbound and Saxenda; the notice separately describes requests for specified other indications and the under-21 EPSDT process.	This is a California program notice, not a nationwide commercial-benefit rule.

On prediabetes: whether prediabetes counts as a qualifying comorbidity depends on the plan's criteria document. Correction, September 2026: an earlier version stated that Anthem excludes prediabetes and that the Wegovy label lists it; neither statement could be verified and both have been removed. If your BMI is 27 to 29.9 and prediabetes is your only weight-related condition, ask the plan directly how it treats it.

The prior authorization process, step by step

Anthem requires prior authorization for all GLP-1 injections, regardless of indication. The process differs slightly between diabetes and weight-loss indications.

For diabetes indications:

1. Prescriber submits prior authorization through the CarelonRx provider channel. Typical required fields: diagnosis code, most recent A1C or fasting glucose with date, and current diabetes medications if any.
2. Turnaround, approval duration and any automatic adjudication rules are set by the plan and are not published; ask the plan. Correction, September 2026: a fax number, a 24-hour adjudication claim and an 80% approval figure that appeared here were unsourced and have been removed.
3. Patient receives approval notification via text or mail. Prescription routes to specialty pharmacy (Accredo or CVS Specialty, depending on plan).

For weight-loss indications:

1. Prescriber submits prior auth with additional required documentation: height, weight, calculated BMI, comorbidity diagnosis codes if BMI is 27 to 29.9, and the 6-month lifestyle intervention records.
2. Manual review by a nurse or pharmacist; the plan's turnaround standard applies.
3. If any required element is missing, the case is denied with a "documentation incomplete" reason code. The prescriber can resubmit with the missing information, but the clock resets.
4. Common denial reasons even with complete documentation: BMI calculated incorrectly, comorbidity diagnosis not on the accepted list, lifestyle program not considered "structured" (e.g., patient self-report of diet changes without provider documentation).

Anthem does not publish submission-to-fill times. Correction, September 2026: median times of 8 and 14 days that appeared here were unsourced and have been removed.

Why weight-loss-only prior auths so often fail on first submission

Anthem does not publish approval rates, and an earlier version of this section built its argument on a 34% figure that could not be verified. Three structural reasons still explain why weight-loss-only requests fail more often than diabetes requests:

Reason 1: The lifestyle documentation standard is higher than prescribers expect. Most prescribers assume that documenting "patient tried diet and exercise" in a single note is sufficient. Plans typically require prospective documentation over a defined period, which means the patient must have been seeing the provider (or a registered dietitian, or a structured program) regularly during that period. A patient who shows up for the first time requesting a GLP-1 prescription cannot meet this standard on day one, even if they truthfully report years of diet attempts.

Reason 2: The FDA indication vs. off-label use confusion. Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg) is FDA-approved only for type 2 diabetes. Wegovy (semaglutide 2.4 mg) is FDA-approved for weight management. If a prescriber writes for "semaglutide 2 mg weekly for weight loss," Anthem denies it as off-label use of a diabetes drug, even though 2 mg is within the Wegovy dose range. The prescription must specify "Wegovy 2.4 mg" to route to the weight-loss coverage pathway.

Similarly, Mounjaro (tirzepatide 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) is approved only for diabetes. Zepbound (tirzepatide 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg) is approved for weight management. The molecules are identical, but the brand name on the prescription determines the coverage pathway. Prescribing Mounjaro for weight loss triggers an automatic denial.

Reason 3: The employer rider adoption lag. Many patients don't know whether their specific plan purchased the obesity rider until they attempt to fill a prescription. Anthem's member portal and ID card don't indicate rider status. The only way to confirm is to call member services or have the prescriber submit a prior auth and see what happens. A denial reading "benefit not covered under this plan" means the employer didn't purchase the benefit.

What most articles get wrong about "medical necessity"

Most insurance explainer articles say that GLP-1 coverage requires "medical necessity," which is technically true but meaningless without defining what Anthem considers medically necessary.

The error: framing "medical necessity" as a clinical judgment call that the prescriber controls. In reality, Anthem defines medical necessity in the policy document, and the definition is a checklist, not a judgment. If the checklist items are met, the drug is medically necessary by definition. If they're not met, no amount of clinical argumentation changes the answer.

The checklist for weight-loss GLP-1s:

• BMI ≥30, or BMI ≥27 with a comorbidity from the accepted list (not the FDA list, Anthem's list)
• Documented lifestyle intervention over the plan's required period
• Prescription for the FDA-approved weight-loss product (Wegovy or Zepbound), not the diabetes product at a weight-loss dose
• No contraindications

A prescriber letter saying "this patient has struggled with obesity for years and I believe this medication is medically necessary" adds zero value to the prior auth if the checklist isn't met. Conversely, if the checklist is met, the letter is unnecessary.

The practical implication: if you don't meet the checklist, appealing the denial on "medical necessity" grounds almost never succeeds. The better strategy is either to meet the checklist (e.g., complete the plan's required lifestyle program and resubmit) or to pursue an alternative outside Anthem's coverage system.

The Medicare Advantage exception that catches everyone

A Medicare Advantage formulary listing must be matched to the requested indication. Coverage for diabetes or another covered indication does not establish coverage for weight management. The GLP-1 Bridge is a separate demonstration, not a universal Anthem Medicare Advantage drug benefit.

The statute: the definition of a covered Part D drug in Social Security Act section 1860D-2(e)(2)(A) excludes drugs that Medicaid may exclude under section 1927(d)(2)(A), which includes "agents when used for anorexia, weight loss, or weight gain" (HHS ASPE issue brief HP-2024-25, November 26, 2024). Correction, September 2026: earlier versions cited section 1862; that was the wrong section.

The exception: the Medicare GLP-1 Bridge, which runs from July 1, 2026 through December 31, 2027 and offers eligible beneficiaries access to Wegovy, the Zepbound KwikPen and Foundayo at $50 a month with prior authorization, outside Part D cost accounting for eligible beneficiaries. CMS uses a central processor for Bridge prior authorization and claims; Part D plans do not have to opt in. CMS information for Part D plans.

Diabetes is a separate coverage pathway. Ozempic or Mounjaro coverage depends on the member's formulary and plan criteria; a diabetes diagnosis alone does not guarantee a particular drug is covered.

Zepbound also carries a non-weight-loss indication: FDA approved it for chronic weight management in November 2023 and for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 (Zepbound prescribing information, revised 08/2026). Correction, September 2026: an earlier version dated the sleep apnea approval to December 2023 and cited a March 2024 CMS clarification that could not be located; both have been removed.

The age-65 transition: patients who have Anthem commercial coverage with the obesity benefit and move to Medicare Advantage must compare their new plan's medication benefit and indication with any Bridge eligibility. Coverage does not automatically carry over from the previous commercial plan. Self-pay alternatives as of September 2026: LillyDirect sells Zepbound vials or KwikPens at $299 (2.5 mg), $399 (5 mg) or $449 (7.5 mg and up) per month when refilled within 45 days; compounded semaglutide had a month-one median of $197 in the Compounded GLP-1 Price Index as of September 3, 2026.

State-by-state variation in Anthem coverage rules

Anthem operates as separate licensed entities in 14 states, and each state's insurance regulation creates slight variations in coverage policy.

Medicaid, as of September 2026: KFF's tracker counted 13 state Medicaid programs covering GLP-1s for obesity as of January 16, 2026, and the trend is toward fewer. California (Medi-Cal), New Hampshire, Pennsylvania and South Carolina ended coverage on January 1, 2026, and MassHealth ended it on July 1, 2026 (KFF). Correction, September 2026: an earlier version listed criteria for eight states and exclusions for six others; none of those entries could be traced to a state document and all have been removed.

California in detail (Anthem Blue Cross Medi-Cal): Anthem's provider bulletin of November 14, 2025 states that effective January 1, 2026 Wegovy, Zepbound and Saxenda were removed from the Medi-Cal Rx Contract Drugs List; claims deny regardless of indication (reject code 70); existing prior authorizations expired; prior authorization is considered only for Wegovy in noncirrhotic MASH or cardiovascular disease and for Zepbound in obstructive sleep apnea; Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity are restricted to type 2 diabetes (reject code 80); and weight-loss requests for members under 21 are reviewed under EPSDT. Central California Alliance for Health confirmed the same change on December 26, 2025.

Commercial plan variation: state benefit mandates can create coverage floors, but this page found none for obesity pharmacotherapy. Correction, September 2026: an earlier version said California AB 290 (effective January 2026) mandated obesity pharmacotherapy coverage and that New York Insurance Regulation 62 did the same. AB 290 of the 2025-2026 session concerns California FAIR Plan automatic payments (approved October 9, 2025), and no Regulation 62 obesity mandate could be located; both claims have been removed. A California bill, SB 1089, would direct the state to partner with a manufacturer under CalRx to lower GLP-1 prices and was pending in August 2026 (CalMatters).

In the absence of a mandate, the obesity benefit remains an employer choice, and Anthem does not publish how many groups elect it.

When to appeal and when to switch strategies

Anthem allows two levels of appeal for prior authorization denials: a standard appeal (decided within 30 days) and an expedited appeal (decided within 72 hours if the prescriber certifies that the delay could seriously jeopardize the patient's health).

When an appeal is worth pursuing:

1. The denial reason is "documentation incomplete" and you can provide the missing documentation. This addresses a stated documentation gap; Anthem does not publish an approval rate for this scenario. If the denial letter says "no lifestyle intervention records provided" and you have those records, resubmit with the documentation attached.

1. The BMI was calculated incorrectly. Anthem's system sometimes pulls height and weight from old records. Compare the measurements used in the decision with a recent provider record and the actual plan criterion.

1. The comorbidity diagnosis is on Anthem's accepted list but wasn't recognized by the system. For example, if you have obstructive sleep apnea diagnosed by sleep study but the prior auth didn't include the sleep study report, submit the report on appeal.

When an appeal is not worth pursuing:

1. The denial reason is "benefit not covered under this plan." Compare the decision with the actual benefit terms and requested indication. That wording does not, by itself, establish why the benefit is absent or predict the outcome of every appeal.

1. The decision says the submitted information does not meet the plan criteria. Compare the named criterion with that plan's current document and the information used in the decision. There is no single Anthem BMI threshold that establishes the outcome for all plans.

1. You're on a Medicare Advantage plan and the drug is outside the Bridge. The statutory exclusion cannot be appealed away. Check first whether the request qualifies under the Medicare GLP-1 Bridge (Wegovy, Zepbound KwikPen or Foundayo, $50 a month with prior authorization, July 1, 2026 to December 31, 2027) or a covered non-weight-loss indication such as Zepbound for obstructive sleep apnea.

Correction, September 2026: this section previously reported a 38-day median appeal resolution time and percentages of denied patients who switched to compounded semaglutide or discontinued. Those figures had no identifiable cohort or source and have been removed. Anthem's appeal timelines are the standard and expedited windows described above.

Compounded semaglutide as the predictable alternative

Compounded semaglutide is semaglutide prepared by a state-licensed compounding pharmacy from bulk API (active pharmaceutical ingredient), not manufactured by Novo Nordisk. It's the same molecule as Ozempic and Wegovy but is not FDA-approved, has not undergone the same manufacturing and quality review, and is not interchangeable with brand-name products.

The coverage advantage: compounded semaglutide is not billed through insurance, so Anthem's coverage rules don't apply. No prior authorization, no employer benefit requirement. The patient pays cash, and the pharmacy ships the medication. A prescriber still has to evaluate the patient and, since the shortage ended, document why a compounded version is needed.

Current pricing (the Compounded GLP-1 Price Index, data as of September 3, 2026):

• Compounded semaglutide: month-one median $197 (range $88 to $299 across 14 providers); month-four median $224 (range $149 to $437 across 12 providers)
• Compounded tirzepatide: month-one median $299 (range $149 to $470 across 14 providers); month-four median $299 (range $179 to $627 across 11 providers)

What a monthly price includes (medication, supplies, shipping, the telehealth visit) varies by provider; read each provider's terms.

The quality question: compounded semaglutide is not subject to FDA manufacturing oversight. The pharmacy must be licensed by the state board of pharmacy and may be accredited by PCAB (Pharmacy Compounding Accreditation Board), but those standards are less stringent than FDA cGMP (current Good Manufacturing Practice) requirements for commercial drug manufacturers.

FDA's statement on unapproved GLP-1 drugs (content current as of September 1, 2026) reports 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide as of May 31, 2026, including dosing errors, some requiring hospitalization, and notes warning letters to sellers of unapproved products. Correction, September 2026: potency-failure percentages of 15% to 30% that appeared here could not be verified and have been removed. Choosing a compounding pharmacy still means verifying state licensure and accreditation, asking for certificates of analysis, and confirming the API source.

FormBlends fills GLP-1 prescriptions through state-licensed 503A compounding pharmacies; other compounded prescriptions are filled by licensed U.S. pharmacies. Your dispensing pharmacy is identified on your prescription label and shipping paperwork. This doesn't eliminate risk, but it reduces it to a level comparable to other compounded injectable medications.

The legal question, as of September 2026: the shortage era is over. FDA determined the tirzepatide shortage resolved on December 19, 2024 and ended shortage-based enforcement discretion for 503A pharmacies on February 18, 2025 and for 503B outsourcing facilities on March 19, 2025; it determined the semaglutide shortage resolved on February 21, 2025, with enforcement discretion ending April 22, 2025 (503A) and May 22, 2025 (503B) (FDA, content current as of April 1, 2026). Compounding of a copy of a commercially available drug is now limited to the ordinary conditions of section 503A, which require a prescriber to document a patient-specific need. Correction, September 2026: an earlier version said both drugs remained on the shortage list as of April 2026 and that pharmacies would have 60 days to stop after removal; both statements were out of date. Availability of compounded GLP-1s can change with enforcement and litigation, so patients should still have a transition plan.

The decision tree: should you fight the denial or move on?

START: Anthem denied your prior authorization for a GLP-1 weight-loss prescription.

Question 1: What was the denial reason?

• "Benefit not covered under this plan": Compare the decision with the actual benefit and indication before selecting another strategy. Go to Question 4 for alternatives.
• "Documentation incomplete": You can provide the missing documentation. Go to Question 2.
• "Does not meet medical necessity criteria": Check whether you actually meet the BMI and comorbidity thresholds. If yes, go to Question 2. If no, go to Question 4.
• "Medicare Part D does not cover drugs for weight loss": You're on Medicare Advantage. Ask whether the request qualifies under the Medicare GLP-1 Bridge (Wegovy, Zepbound KwikPen, Foundayo; $50 a month; July 1, 2026 to December 31, 2027) or a covered non-weight-loss indication. A determination about a specific request cannot be predicted from Medicare Advantage enrollment alone. Go to Question 4 for alternatives.

Question 2: Do you have the missing documentation or can you obtain it within 2 weeks?

• Yes: File a standard appeal with the documentation attached. If approved, you're done. If denied again, go to Question 4.
• No: Go to Question 3.

Question 3: Can you meet the documentation requirement if you wait 6 months?

• Yes: Enroll in a structured weight-loss program (hospital-based, registered dietitian, or a program that provides attendance records). Document the program in your medical record at each provider visit. Resubmit the prior auth after the plan's required period.
• No: Go to Question 4.

Question 4: Is your priority speed (starting medication within 2 weeks) or cost (lowest monthly out-of-pocket)?

• Speed: Compounded semaglutide, if a prescriber determines it is appropriate for you. No prior auth. Month-one median $197 in the Compounded GLP-1 Price Index as of September 3, 2026. You're done.
• Cost: Compare three dated numbers: your brand copay after deductible; LillyDirect self-pay Zepbound at $299 to $449 a month (or the Zepbound savings card at as little as $25 if your commercial plan covers it, $499 if it does not); and the compounded median of $197 for semaglutide or $299 for tirzepatide. Pick the lowest that a prescriber supports. You're done.

Question 5: If compounded semaglutide becomes unavailable to you, what's your backup plan?

• I'll transition to brand-name if I can get coverage by then: Make sure you're documenting lifestyle interventions now so you can resubmit a prior auth if compounding becomes unavailable.
• I'll discontinue GLP-1 therapy: Understood. Since FDA declared the shortages resolved in 2024 and 2025, compounded semaglutide depends on a prescriber's patient-specific documentation and on enforcement policy, so treat it as contingent rather than permanent.

Correction, September 2026: what was removed from this page and why

As of September 5, 2026, this page was checked against Anthem and Elevance Health publications, the Medi-Cal Rx provider bulletin, HHS and FDA documents, KFF's Medicaid tracker, Lilly's published pricing and the FormBlends price index. Statistics that could not be traced to any published source were removed rather than restated: the 34% first-submission approval rate and its 66% mirror image, employer adoption rates of 41%, 28% and 52%, appeal approval rates of 70% to 85%, a 30% share of benefit-not-covered denials, 8-day and 14-day fill times, a 38-day appeal median with 78%, 64% and 14% splits, copay ranges by tier, an A1C 7.0% threshold, numeric comorbidity cutoffs, a fax number and 15% to 30% potency failures. Two policy references (PHARMACY.00082 and an IngenioRx Q4 2025 report), two state mandates (California AB 290 and New York Regulation 62) and an eight-state Medicaid table were removed because they could not be located or were shown to be wrong. IngenioRx was renamed CarelonRx on January 1, 2023; the Part D statute is section 1860D-2(e)(2)(A), not 1862; Zepbound's sleep apnea approval was December 2024; and the shortage-era compounding language was replaced with FDA's dated resolution.

Medicare changed on July 1, 2026: the GLP-1 Bridge

For two decades the answer to "does Medicare cover weight-loss drugs" was no, because the Part D statute excludes agents used for anorexia, weight loss or weight gain (Social Security Act section 1860D-2(e)(2)(A), incorporating section 1927(d)(2)(A); HHS ASPE issue brief HP-2024-25, November 26, 2024). That is still the baseline. The separate Medicare GLP-1 Bridge has its own eligibility and administration. The following compares its benefit with ordinary Part D coverage using CMS provider information:

Bridge feature	What the current CMS source establishes
Dates	July 1, 2026 through December 31, 2027
Named products and formulations	Wegovy injection and tablets; Foundayo; Zepbound KwikPen. Zepbound single-dose pens and vials are not Bridge formulations.
Member cost	$50 per monthly supply for eligible beneficiaries, separate from Part D out-of-pocket accounting.
Coverage population	Eligible Part D plan types and the demonstration's clinical criteria; Medicare Advantage enrollment by itself does not establish eligibility.
Administration	CMS central processor for prior authorization and claims. Plan opt-in is not required.
Other covered indications	Requests coverable under ordinary Part D are handled through that benefit, not shifted to Bridge merely because a drug is absent from the formulary.

Two other routes remain for Anthem Medicare Advantage members. Diabetes: Ozempic and Mounjaro may be covered for type 2 diabetes under the member's formulary and plan criteria. Sleep apnea: FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024 (label revised 08/2026), a non-weight-loss indication that Part D can cover under plan criteria. Ask the plan how it administers each.

California Medi-Cal (Anthem Blue Cross) stopped covering weight-loss GLP-1s on January 1, 2026

Anthem Blue Cross's provider bulletin "GLP-1 Coverage Considerations" (CA-BC-CD-001363-25, November 14, 2025) lays out the change for Medi-Cal members:

• Effective January 1, 2026, Wegovy, Zepbound and Saxenda were removed from the Medi-Cal Rx Contract Drugs List. Claims deny with reject code 70 regardless of indication, and existing prior authorizations expired.
• Prior authorization is considered only for Wegovy in noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) or cardiovascular disease, and for Zepbound in obstructive sleep apnea.
• Ozempic, Rybelsus, Mounjaro, Victoza, Byetta, Bydureon and Trulicity are restricted to type 2 diabetes (reject code 80).
• Weight-loss requests for members under 21 are reviewed under EPSDT.

Central California Alliance for Health confirmed the same Medi-Cal Rx change on December 26, 2025. Nationally, KFF counted 13 state Medicaid programs covering GLP-1s for obesity as of January 16, 2026; New Hampshire, Pennsylvania and South Carolina ended coverage the same day as California, and MassHealth followed on July 1, 2026. Separately, California's SB 1089, which would have the state partner with a manufacturer under CalRx to lower GLP-1 prices, was pending in August 2026 (CalMatters).

What compounded GLP-1s cost and where they stand legally (September 2026)

Prices, from the Compounded GLP-1 Price Index with data as of September 3, 2026: compounded semaglutide month-one median $197 (range $88 to $299, 14 providers) and month-four median $224 (range $149 to $437, 12 providers); compounded tirzepatide month-one median $299 (range $149 to $470, 14 providers) and month-four median $299 (range $179 to $627, 11 providers). The brand comparators as of September 4, 2026: Mounjaro list price $1,112.16 per fill; Zepbound savings card as little as $25 for covered commercial patients (caps $100 a month, $1,300 a year, through December 31, 2026) and $499 for commercially insured patients whose plan does not cover it; LillyDirect self-pay Zepbound $299, $399 or $449 a month by dose when refilled within 45 days.

Legal status: FDA determined the tirzepatide shortage resolved on December 19, 2024 and the semaglutide shortage on February 21, 2025, and ended shortage-based enforcement discretion for 503A pharmacies on February 18 and April 22, 2025 respectively (503B: March 19 and May 22, 2025). Compounded versions now depend on a prescriber documenting a patient-specific need under section 503A. FDA had received 990 adverse event reports involving compounded semaglutide and more than 730 involving compounded tirzepatide as of May 31, 2026, including dosing errors, some requiring hospitalization (FDA statement, content current as of September 1, 2026). Compounded products are not FDA approved and are not interchangeable with Wegovy or Zepbound.

FAQ

Does Anthem cover Ozempic for weight loss?

No. Anthem covers Ozempic only for type 2 diabetes. If you want semaglutide for weight loss, the prescription must be for Wegovy (the FDA-approved weight-loss formulation), and your employer must have purchased the obesity benefit rider. Prescribing Ozempic off-label for weight loss results in an automatic denial.

Does Anthem Medicare Advantage cover Wegovy or Zepbound?

For weight management, eligible beneficiaries may access the named products through the Medicare GLP-1 Bridge. For other covered indications, the applicable Part D formulary and criteria govern the request. The Bridge is not a guarantee that every Anthem Medicare Advantage member or every presentation qualifies. Otherwise Part D excludes agents used for weight loss by statute (Social Security Act section 1860D-2(e)(2)(A), via section 1927(d)(2)(A)), and that exclusion cannot be appealed away. Zepbound for obstructive sleep apnea is a separate, non-weight-loss indication.

What BMI do I need for Anthem to cover weight loss injections?

Plans that cover weight-loss GLP-1s generally follow the FDA labels: BMI 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease. Which conditions qualify, including whether prediabetes counts, is set by your plan's criteria document; an earlier statement here that Anthem excludes prediabetes could not be verified and has been removed.

How long does Anthem prior authorization take for GLP-1s?

Anthem does not publish turnaround figures for GLP-1 prior authorizations; the plan's standard and expedited review windows apply. Weight-loss requests go to manual review and take longer than diabetes requests because they require more documentation. If documentation is incomplete, the case is denied and the clock resets when you resubmit.

Can I appeal an Anthem denial for weight loss medication?

Yes, but success depends on the denial reason. If the denial is "documentation incomplete" and you can provide the missing documentation, an appeal is worth filing. A benefit exclusion and missing clinical documentation are different denial reasons. The result depends on the actual benefit terms, requested indication and decision, so the article cannot predict that every appeal will fail. CMS states that the Bridge does not change Part D appeal and exception rights. Anthem does not publish appeal approval rates.

Does Anthem cover compounded semaglutide?

No. Compounded medications are not billed through insurance. You pay cash, and Anthem is not involved. The advantage is no prior authorization requirement. The disadvantage is no insurance subsidy.

What's the copay for Wegovy or Zepbound with Anthem?

Depends on your plan's specialty tier structure and deductible; Anthem publishes no single figure, and tier copay ranges that appeared here earlier were unsourced and have been removed. For reference, the Zepbound savings card brings a covered commercial prescription to as little as $25 a month (savings capped at $100 for a 1-month fill and $1,300 a year, through December 31, 2026), the Mounjaro card to as little as $25 (caps $150 a month, $1,950 a year), and Mounjaro's list price is $1,112.16 per fill.

How do I know if my Anthem plan has the obesity rider?

Call Anthem member services (the number on the back of your ID card) and ask whether your plan covers "anti-obesity medications" or "GLP-1 agonists for weight management." The member portal and ID card don't indicate rider status. Alternatively, have your prescriber submit a prior auth and see whether the denial reason is "benefit not covered" (no rider) or something else.

Does Anthem cover Mounjaro for weight loss?

No. Mounjaro is FDA-approved only for type 2 diabetes. If you want tirzepatide for weight loss, the prescription must be for Zepbound. Prescribing Mounjaro off-label for weight loss results in an automatic denial, even if the dose is the same as Zepbound.

What counts as a "structured weight-loss program" for Anthem prior auth?

A program with documented enrollment, attendance records, and provider involvement. Examples: hospital-based weight management programs, registered dietitian visits, Weight Watchers or Noom with attendance logs submitted to your provider. Self-reported diet changes without provider documentation do not meet the standard.

Can I use a GoodRx coupon for Wegovy if Anthem denies coverage?

Discount-card pricing for brand GLP-1s was not verified for this update. The manufacturers' own programs are the sourced options: Lilly sells self-pay Zepbound through LillyDirect at $299, $399 or $449 a month by dose when refilled within 45 days, and commercially insured patients whose plan does not cover Zepbound can pay $499 with the savings card. Compounded semaglutide had a month-one median of $197 in the FormBlends price index as of September 3, 2026.

Does Anthem cover GLP-1s for PCOS or fatty liver disease?

Not as standalone indications. If you have PCOS or fatty liver disease plus type 2 diabetes, coverage is available under the diabetes pathway. If you have PCOS or fatty liver disease without diabetes, coverage is available only under the weight-loss pathway (BMI ≥30 or ≥27 with comorbidity, employer must have purchased the rider).

What happens if I lose weight on a GLP-1 and my BMI drops below 30?

Plans reassess medical necessity at each prior authorization renewal; the renewal interval is set by the plan. If your BMI drops below 27, coverage may be discontinued on the grounds that you no longer meet the medical necessity criteria. The policy doesn't explicitly address this scenario, so it's decided case-by-case during the renewal review.

Can my doctor write a letter to get Anthem to cover weight loss medication?

A letter helps only if you meet all the checklist criteria and the denial was due to incomplete documentation. If you don't meet the BMI threshold, don't have an accepted comorbidity, or your employer didn't purchase the rider, a letter won't change the outcome. Anthem's medical necessity determination is based on the policy checklist, not clinical judgment.

Does Anthem cover Saxenda (liraglutide) for weight loss?

Yes, if your employer purchased the obesity rider. Saxenda is a daily injection (not weekly like Wegovy or Zepbound), and the prior authorization criteria follow the same pattern: BMI 30 or higher, or 27 or higher with a weight-related condition, plus lifestyle documentation over the plan's required period. Note that Medi-Cal removed Saxenda along with Wegovy and Zepbound from its weight-loss coverage on January 1, 2026.

Does Anthem Medicare Advantage cover Zepbound for sleep apnea?

It can, under plan criteria. FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024, and that indication appears on the label revised 08/2026. Because it is not a weight-loss use, the Part D statutory exclusion does not apply to it. Separately, eligible beneficiaries can access the Zepbound KwikPen for weight management through the Bridge; this is distinct from a Part D request for sleep apnea.

Which state Medicaid programs cover GLP-1s for obesity in 2026?

Fewer than before. KFF's Medicaid coverage tracker counted 13 states covering GLP-1s for obesity as of January 16, 2026. California (Medi-Cal), New Hampshire, Pennsylvania and South Carolina ended coverage on January 1, 2026, and MassHealth ended it on July 1, 2026. Anthem administers Medicaid plans in some states, so the answer depends on the state's Contract Drugs List rather than on Anthem; Medi-Cal's January 2026 bulletin is the clearest example.

What is the Zepbound savings card worth if my Anthem plan covers it?

Per Lilly's coverage and savings page (seen September 4, 2026), commercially insured patients whose plan covers Zepbound can pay as little as $25 per fill, with savings capped at $100 for a 1-month, $200 for a 2-month and $300 for a 3-month fill, $1,300 per calendar year and 13 fills, through December 31, 2026. If the plan does not cover Zepbound, the card price is $499 a month. Medicare and Medicaid members are not eligible for manufacturer cards.

Related guides

• Does Anthem Cover Wegovy for Weight Loss? The 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When You're Denied
• Does Anthem Cover Zepbound? Coverage Rules, Prior Authorization, and What to Do If You're Denied
• Does Anthem Blue Cross Cover Zepbound? 2026 Coverage Rules, Prior Authorization Requirements, and What to Do When You're Denied
• Does Aetna Cover Ozempic for Weight Loss? The 2026 Coverage Rules and What Happens When You're Denied
• Does Anthem Cover Wegovy in 2026? The Complete Prior Authorization Map and What to Do When Coverage Is Denied
• Does Anthem Blue Cross Cover Wegovy? The 2026 Coverage Map, Prior Authorization Process, and What to Do When Denied
• Tool: cost calculator

Sources

1. Social Security Act sections 1860D-2(e)(2)(A) and 1927(d)(2)(A) (Part D exclusion of agents used for anorexia, weight loss, or weight gain), as described in HHS ASPE issue brief HP-2024-25, November 26, 2024. https://aspe.hhs.gov/sites/default/files/documents/127bd5b3347b34be31ac5c6b5ed30e6a/medicare-coverage-anti-obesity-meds.pdf
2. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (tirzepatide shortage resolved December 19, 2024; semaglutide February 21, 2025), content current as of April 1, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
3. Novo Nordisk. Wegovy Prescribing Information. Revised December 2025.
4. Eli Lilly and Company. Zepbound (tirzepatide) Prescribing Information (indications: chronic weight management; obstructive sleep apnea), revised 08/2026. https://pi.lilly.com/us/zepbound-uspi.pdf
5. Pharmacy Compounding Accreditation Board. Accreditation Standards for Compounding Pharmacies. 2025 edition.
6. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (990 compounded semaglutide and 730+ compounded tirzepatide adverse event reports as of May 31, 2026), content current as of September 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
7. Garvey W et al. American Association of Clinical Endocrinologists and American College of Endocrinology Position Statement on Obesity Treatment. Endocrine Practice. 2023.
8. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
9. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
10. Anthem Blue Cross (California Medi-Cal). GLP-1 Coverage Considerations, provider bulletin CA-BC-CD-001363-25, November 14, 2025. https://providers.anthem.com/docs/gpp/california-provider/CA_MMP_GLP1Coverage.pdf?v=202512241809
11. Central California Alliance for Health. GLP-1 drug changes effective starting January 2026, December 26, 2025. https://thealliance.health/glp-1-drug-changes-effective-starting-january/
12. healthinsurance.org. Does health insurance cover drugs used for weight loss (Medicare GLP-1 Bridge: $50 a month, July 1, 2026 to December 31, 2027, Wegovy, Zepbound KwikPen, Foundayo), checked September 4, 2026. https://www.healthinsurance.org/faqs/does-health-insurance-cover-drugs-used-for-weight-loss-such-as-ozempic-wegovy-mounjaro-and-zepbound/
13. KFF. Medicaid coverage of and spending on GLP-1s (13 states covering for obesity as of January 16, 2026; CA, NH, PA, SC ended January 1, 2026; MassHealth July 1, 2026). https://www.kff.org/medicaid/medicaid-coverage-of-and-spending-on-glp-1s/
14. Elevance Health. Our companies (Anthem Blue Cross and Blue Shield offered in 14 states; CarelonRx), seen September 5, 2026. https://www.elevancehealth.com/who-we-are/companies
15. Fierce Healthcare. Anthem launches Carelon, Wellpoint brands ahead of Elevance Health rebrand (IngenioRx renamed CarelonRx effective January 1, 2023), June 2022.
16. Eli Lilly and Company. Zepbound savings card and coverage ($25 with caps $100/$200/$300 per fill, $1,300 a year, 13 fills, through December 31, 2026; $499 not covered), seen September 4, 2026. https://zepbound.lilly.com/coverage-savings
17. Eli Lilly and Company. Mounjaro savings and coverage (list price $1,112.16 per fill; card caps $150/$300/$450 and $1,950 a year), seen September 4, 2026. https://mounjaro.lilly.com/savings-coverage
18. Eli Lilly and Company. LillyDirect Zepbound self-pay pricing ($299, $399, $449 with refill within 45 days), seen September 4, 2026. https://www.lilly.com/lillydirect/zepbound
19. FormBlends. Compounded GLP-1 Price Index, data as of September 3, 2026. https://formblends.com/report/data/compounded-glp1-price-index
20. California Legislature. AB 290 (2025-2026), California FAIR Plan Association: automatic payments, approved October 9, 2025 (cited to document that it is not an obesity coverage mandate). https://leginfo.legislature.ca.gov/faces/billStatusClient.xhtml?bill_id=202520260AB290
21. CalMatters. GLP-1 weight loss drugs, cost and affordability in California (SB 1089, CalRx partnership pending), August 2026. https://calmatters.org/health/2026/08/glp-weight-loss-cost-affordability-california/

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, and Trulicity are registered trademarks of their respective manufacturers. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, Eli Lilly, or any other pharmaceutical manufacturer. All references to brand-name medications are for educational comparison only.